Prostatype Genomics has received the first order of Prostatype in Switzerland from one of the country's major university hospitals. It is a breakthrough for the company, where the focus now is on ensuring routine use through continued close collaboration with the customer and expanding the use of Prostatype® to additional leading hospitals in the country. The revenue will be booked in Fourth Quarter 2023.

Prostatype Genomics has received the first order for the company's product Prostatype® in Switzerland, one of the company's priority target markets. Prostatype® is a genetic test for assessing the aggressiveness of prostate cancer, which is of great importance in the often difficult situation patients and healthcare find themselves in when assessing whether a patient should undergo radical treatment or not. The customer is one of the country's larger university hospitals with previous experience with prognostic biomarkers for use in diagnosed prostate cancer.